Protocol Ledger

NCT02616484 · Phase III · ACTIVE NOT RECRUITING

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

Interventional Phase III clinical trial protocol NCT02616484 sponsored by Saol Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-14 Enrollment: 34 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT02616484
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)34 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT02616484
Protocol FieldVerified Registry Value
NCT IdentifierNCT02616484
Consolidated Lead SponsorSaol Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment34 participants (ACTUAL)
Registered Start Date2020-07-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI